Evolva starts Phase I Clinical Trials on EV-077

20-Mar-2009 - Switzerland

Evolva SA announced it has started Phase I clinical trials with its drug candidate EV-077-3201-2TBS. The first-in-man study, a single ascending dose study, will enroll 56 healthy male volunteers and will be conducted in Germany over the next 12 weeks. The purpose of the study is to assess the safety and tolerability of EV-077-3201-2TBS and evaluate its pharmacokinetic profile and pharmacodynamic effects.

Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased and excited to have reached a significant Milestone by entering Phase I studies with our first drug candidate. We believe that EV-077-3201-2TBS has a very interesting potential in a number of cardiovascular and renal indications.”

EV-077-3201-2TBS is a new chemical entity, with a different mode of action from existing drugs that are being developed for cardiovascular and renal indications.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...